| Li, Xiaoying |
NCT05816057: A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus |
|
|
| Completed | 3 | 476 | RoW | semaglutide injection | Hangzhou Jiuyuan Gene Engineering Co. Ltd., | Diabetes Mellitus, Type 2 | 07/23 | 10/23 | | |
SURMOUNT-OSA, NCT05412004: Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea |
|
|
| Completed | 3 | 469 | Europe, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Sleep Apnea, Obesity | 03/24 | 03/24 | | |
NCT05834868: Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes |
|
|
| Recruiting | 3 | 805 | RoW | THDB0206 Injection, Insulin Lispro Injection | Tonghua Dongbao Pharmaceutical Co.,Ltd | Type 2 Diabetes | 03/24 | 10/24 | | |
NCT06396429: To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese |
|
|
| Recruiting | 3 | 540 | RoW | HRS9531 injection, Placebo | Fujian Shengdi Pharmaceutical Co., Ltd. | Overweight or Obesity | 07/25 | 08/25 | | |
NCT05680129: A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM |
|
|
| Active, not recruiting | 3 | 623 | RoW | Ecnoglutide high dosage, XW003, Ecnoglutide low dosage, Dulaglutide, Metformin | Hangzhou Sciwind Biosciences Co., Ltd. | T2DM, Type 2 Diabetes Mellitus | 10/24 | 10/24 | | |
NCT05702073: To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin. |
|
|
| Recruiting | 3 | 400 | RoW | INS068 injection, Insulin Glargine | Jiangsu HengRui Medicine Co., Ltd. | Type 2 Diabetes Mellitus | 10/24 | 10/24 | | |
NCT05881837: Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes |
|
|
| Active, not recruiting | 2 | 249 | RoW | HRS9531 injection, HRS9531 injection Placebo | Fujian Shengdi Pharmaceutical Co., Ltd. | Overweight or Obesity | 10/24 | 10/24 | | |
| Not yet recruiting | 2 | 180 | NA | HDM1002 100 mg QD, HDM1002, HDM1002 200 mg QD 12weeks, HDM1002 400 mg QD 12weeks, Placebo | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Overweight and Obesity | 10/24 | 11/24 | | |
| Active, not recruiting | 2 | 145 | Europe, Canada, Japan, US, RoW | GSK3858279, Placebo | GlaxoSmithKline | Pain | 10/24 | 01/25 | | |
NCT05516966: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 1 | 64 | RoW | HRS9531, Placebo, Dulaglutide Injection | Fujian Shengdi Pharmaceutical Co., Ltd. | Diabetes Mellitus, Type 2 | 05/23 | 05/23 | | |
NCT06520540: HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects |
|
|
| Not yet recruiting | 1 | 72 | RoW | HDM1002 100 mg QD 12weeks, HDM1002 200 mg QD 12weeks, HDM1002 400 mg QD 12weeks，Q 2W for titration, HDM1002 400 mg QD 12weeks，Q 3W for titration, Placebo | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Glucagon-Like Peptide-1 Receptor Agonists | 11/24 | 12/24 | | |
NCT06427642: Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases |
|
|
| Recruiting | N/A | 120 | RoW | Mononuclear cells, Mild hypothermia therapy, Breathing support technique, Total parenteral nutrition | Shandong Qilu Stem Cells Engineering Co., Ltd., Qilu Children's Hospital of Shandong University | Hypoxic-Ischemic Encephalopathy, Bronchopulmonary Dysplasia, Short Bowel Syndrome | 05/24 | 04/25 | | |
| Liu, Lin |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 60 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Non-Hodgkin's Lymphoma | 12/24 | 09/25 | | |
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | 2 | 186 | RoW | Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Systemic Lupus Erythematosus, SLE | 08/25 | 05/26 | | |
NCT06387082: A Clinical Study of HMPL-506 in Patients With Hematological Malignancies |
|
|
| Recruiting | 1 | 98 | RoW | HMPL-506, Two strengths of HMPL-506 tablets (25 mg and 100 mg) will be used for this clinical study | Hutchmed | Hematological Malignancies | 10/27 | 12/27 | | |
NCT04606433: Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1 | 41 | RoW | GNC-038 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | 06/25 | 11/25 | | |
